Skip to main content

Table 1 Clinical characteristics of women with and without BRCAfounder mutations

From: A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

Variable

No BRCA founder mutation (n = 440)

BRCA1 founder mutation (n = 43)

P (BRCA1 versus no founder mutation)*

BRCA2 founder mutation (n = 14)

P (BRCA2 versus no founder mutation)*

Age at diagnosis (years)

     

   < 50

135 (31%)

30 (70%)

< 0.0001

4 (29%)

NS

   ≥ 50

305 (69%)

13 (30%)

 

10 (71%)

 

Tumor size

     

   T1

324 (74%)

29 (67%)

NS

8 (57%)

NS

   T2

97 (22%)

11 (26%)

 

4 (29%)

 

   Unknown

19 (4%)

3 (7%)

 

2 (14%)

 

Nodal involvement

     

   Present

149 (34%)

18 (42%)

NS

6 (43%)

NS

   Absent

262 (60%)

23 (53%)

 

6 (43%)

 

   Unknown

29 (6%)

2 (5%)

 

2 (14%)

 

Estrogen receptor

     

   Positive

197 (45%)

6 (14%)

< 0.0001

7 (50%)

NS

   Negative

98 (22%)

27 (63%)

 

3 (21%)

 

   Unknown

145 (33%)

10 (23%)

 

4 (29%)

 

Chemotherapy

     

   Yes

156 (35%)

24 (56%)

0.02

7 (50%)

NS

   No

257 (58%)

17 (40%)

 

7 (50%)

 

   Unknown

27 (10%)

2 (4%)

 

0 (0%)

 

Tamoxifen

     

   Yes

190 (43%)

10 (23%)

0.01

9 (64%)

NS

   No

203 (46%)

30 (70%)

 

5 (36%)

 

   Unknown

47 (11%)

3 (7%)

 

0 (0%)

 
  1. *Cases in which the characteristic of interest is unknown are not included in the comparisons. Woman with both BRCA1 and BRCA2 founder mutations are included in both groups, hence the total number women listed here is 497.